About FORUM Pharmaceuticals
FORUM Pharmaceuticals, formerly known as EnVivo Pharmaceuticals, is a biopharmaceutical company dedicated to discovering and developing therapeutics for disorders of the central nervous system (CNS).
FORUM Pharmaceuticals Patents
FORUM Pharmaceuticals has filed 24 patents.
Nicotinic agonists, Nicotinic antagonists, Nootropics, Amines, Psychiatric diagnosis
Nicotinic agonists, Nicotinic antagonists, Nootropics, Amines, Psychiatric diagnosis
Latest FORUM Pharmaceuticals News
Nov 19, 2020
Search jobs 19-Nov-2020 Histone Deacetylase Inhibitors Market Undertakes Strapping Growth by 2020 with Novartis AG, Celleron Therapeutics, FORUM Pharmaceuticals, Pfizer, AstraZeneca, Aurobindo Pharma, Trovagene Global Histone Deacetylase Inhibitors Market report brings into light key market dynamics of the sector. It provides guidelines about planning of advertising and sales promotion efforts. The market report is a professional yet exhaustive study on the current state for the market. This world class market research report is a vital document in planning business objectives or goals. The credible market report is a window to the industry which talks about what market definition, classifications, applications, engagements and market trends are. While formulating this Histone Deacetylase Inhibitors Market analysis report, client business competence is understood adeptly to identify tangible growth opportunities. Get Exclusive FREE Sample Copy of This Report Here https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-histone-deacetylase-inhibitors-market The wide ranging Histone Deacetylase Inhibitors Market report evaluates CAGR value fluctuation during the forecast period of 2021-2028 for the market. All the data of research and analysis are mapped in an actionable model, with strategic recommendations from the experts. Base year for calculation in the report is considered as 2020 while the historic year is 2019 which will tell how the Histone Deacetylase Inhibitors Market is going to act upon in the forecast years by giving information about the several market insights. Lastly, the large scale report makes some important proposals for a new project of the market before evaluating its feasibility. Global histone deacetylase inhibitors market is rising gradually with a healthy CAGR of 14.2% in the forecast period of 2020-2027. The report contains data of the base year 2019 and historic year 2018. Prevailing cases of neurological disorders and other chronic diseases creates avenues for this market growth Few of the major competitors currently working in the global histone deacetylase inhibitors market are Midatech Pharma PLC, Crystal Genomics, CELGENE CORPORATION, Novartis AG, Shenzhen Chipscreen Biosciences Co., Ltd., Spectrum Pharmaceuticals, Inc., Merck & Co., Inc., Celleron Therapeutics, FORUM Pharmaceuticals Inc., Pfizer Inc., AstraZeneca, Eisai Co., Ltd., REGENACY PHARMACEUTICALS, LLC, Karyopharm Therapeutics, Aurobindo Pharma, Trovagene, Wellness Pharma International, Syndax, MEI Pharma Inc., Onxeo among others. Read Complete Details with TOC Here https://www.databridgemarketresearch.com/toc?dbmr=global-histone-deacetylase-inhibitors-market Market Definition: Global Histone Deacetylase Inhibitors Market Histone deacetylase inhibitors are chemotherapy agents that inhibit histone deacetylases. These agents cause apoptosis and cell death. Histone deacetylase inhibitors are newer class of anti-cancer drugs used for treatment of T-cell lymphoma and myeloma. The drugs show good effects for hematological malignancies and epigenetic or non-epigenetic regulations. According to World Health Organization (WHO), approximately 9.6 million deaths are reported in 2018 by cancer which includes lung, prostate, stomach and liver cancer as the most common types of cancers. The histone deacetylase inhibitor drugs show good activity for treatment of these diseases with lesser side effects. Segmentation: Global Histone Deacetylase Inhibitors Market Histone Deacetylase Inhibitors Market : By Classification Class I HDACs Oncology Vorinostat Oral Hospitals Hospital Pharmacy North America Key Developments in the Histone Deacetylase Inhibitors Market: In October 2019, Midatech Pharma PLC received Orphan Drug designation from the U. S. FDA for MTX110, a non-selective histone deacetylase inhibitor used for treatment of patients with malignant glioma and diffuse intrinsic pontine glioma (DIPG). This designation will support the development of drug candidate and accelerate its approval In August 2019, Crystal Genomics received the Orphan Drug designation from the U. S. FDA for CG-745, a histone deacetylase (HDAC) inhibitor drug candidate used for treatment of patients with pancreatic cancer. This designation will support the development of drug candidate and accelerate its approval Some of the Major Highlights of TOC covers: Chapter 1: Methodology & Scope About Data Bridge Market Research: Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate. Contact Us
FORUM Pharmaceuticals Frequently Asked Questions (FAQ)
When was FORUM Pharmaceuticals founded?
FORUM Pharmaceuticals was founded in 2001.
Where is FORUM Pharmaceuticals's headquarters?
FORUM Pharmaceuticals's headquarters is located at 480 Arsenal Street, Watertown.
What is FORUM Pharmaceuticals's latest funding round?
FORUM Pharmaceuticals's latest funding round is Dead.
How much did FORUM Pharmaceuticals raise?
FORUM Pharmaceuticals raised a total of $127.7M.
Who are the investors of FORUM Pharmaceuticals?
Investors of FORUM Pharmaceuticals include F-Prime Capital, BCM Technologies, Cogene Ventures, Baylor College of Medicine, BioTex Finance and 5 more.
Who are FORUM Pharmaceuticals's competitors?
Competitors of FORUM Pharmaceuticals include Orexigen Therapeutics, BrainCells, Galenea, Inspire Pharmaceuticals, Tranzyme Pharma and 11 more.
Compare FORUM Pharmaceuticals to Competitors
BrainCells is a biopharmaceutical company focused on the development of small molecule therapeutics for diseases of the central nervous system (CNS). The company's technology platform is based on research in the field of neurogenesis and recent discoveries linking neurogenesis to CNS disease states. BCI is using its neurogenesis technology platform to identify clinical-stage compounds, targets and compounds optimal for CNS indications. BCI is building a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes and other CNS disorders.
Sound Pharmaceuticals (SPI) is a biopharmaceutical company that develops prescription drugs that will enable doctors and patients to prevent and treat hearing loss, a disease that affects over 30 to 40 million Americans. It was founded in 2002 and is based in Seattle, Washington.
Janus Pharmaceuticals Inc. (Janus) is a specialty pharmaceutical company identifying, acquiring and aggressively developing topical prescription products for treatment of skin infections. Determined to be the "Dermal Alternative", Janus has already established a strong intellectual property portfolio for topical anti-infective compounds that would be rapidly commercialized through fast regulatory pathways. Led by an accomplished management team and board located in the US and Japan, Janus has trans-Pacific network and resources in the biopharmaceutical industry.
arGentis Pharmaceuticals is a diversified specialty biopharmaceutical company seeking to license and commercialize therapies with demonstrated proof of concept for chronic diseases.
Galenea is a biopharmaceutical company discovering and developing drugs to treat schizophrenia and other central nervous system diseases. The company has developed technology, the MANTRA (Multiwell, Automated NeuroTRansmission Assay) system, which enables direct high throughput screening of synaptic function in cultured primary neurons from mice and rats, and in neurons derived from human induced pluripotent stem cells. The company is using the MANTRA system to characterize synaptic dysfunctions in disease models and to identify signatures of therapeutic compound classes.
Inflazyme Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of respiratory and inflammatory diseases. The company's core focus is medicinal chemistry based, orally active, small molecules aimed at treating unmet medical needs.